Evidence map›Paper›PMID 35581350›Full record

ArticleCellular & molecular immunology2022

Retinoic acid signaling acts as a rheostat to balance Treg function.

Govindarajan Thangavelu, Gabriela Andrejeva, Sara Bolivar-Wagers, Sujeong Jin, Michael C Zaiken, Michael Loschi, Ethan G Aguilar, Scott N Furlan, Chrysothemis C Brown, Yu-Chi Lee and 15 more

Open access · greenAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Elevated Peripheral CD161ACR open rheumatology · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 3 countries.

Govindarajan ThangaveluDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA. govindarajan.thangavelu@gmail.com.
Gabriela AndrejevaCenter for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-3508-7682
Sara Bolivar-WagersDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Sujeong JinDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Michael C ZaikenDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Michael LoschiDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-4460-5939
Ethan G AguilarDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Scott N FurlanDepartment of Pediatrics, University of Washington, Seattle, WA, USA.
Chrysothemis C BrownHoward Hughes Medical Institute, Immunology Program, and Ludwig Center, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu-Chi LeeDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, USA.
Cameron McDonald HymanDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Colby J FeserDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Angela Panoskaltsis-MortariDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Keli L HippenDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
Kelli P MacDonaldDepartment of Immunology, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute and School of Medicine, University of Queensland, Brisbane, QLD, Australia.
William J MurphyDepartment of Dermatology, School of Medicine, University of California, Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0002-2793-401X
Ivan MaillardDivision of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1312-6748
Geoffrey R HillFred Hutchinson Cancer Research Center, Seattle, WA, USA.
David H MunnGeorgia Cancer Center, Augusta University, Augusta, GA, USA.
Robert ZeiserDepartment of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Centre, Freiburg, Germany.
Leslie S KeanBoston Children's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA.
Jeffrey C RathmellCenter for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Hongbo ChiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9997-2496
Randolph J NoelleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, USA.
Bruce R BlazarDepartment of Pediatrics, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota Medical Center · USDartmouth College · USVanderbilt University Medical Center · USAugusta University Health · USBoston Children's Hospital · USFred Hutch Cancer Center · USMemorial Sloan Kettering Cancer Center · USSt. Jude Children's Research Hospital · USThe University of Queensland · AUUniversity Medical Center Freiburg · DEUniversity of California, Davis · USUniversity of Minnesota · USUniversity of Pennsylvania · USUniversity of Washington · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
Reprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Role of IDO malignancyR01CA096651 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2016
$3.3M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
PTEN, Tregs and MDSCs in the tumor microenvironmentR01CA211229 · NCI · AUGUSTA UNIVERSITY · PI MUNN, DAVID H. · 2017 to 2021
$1.7M
NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA096651NCI NIH HHS R01 CA103320NCI NIH HHS R01 CA211229NHLBI NIH HHS F30 HL156312NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI091627NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Regulatory T cells (Tregs) promote immune homeostasis by maintaining self-tolerance and regulating inflammatory responses. Under certain inflammatory conditions, Tregs can lose their lineage stability and function. Previous studies have reported that ex vivo exposure to retinoic acid (RA) enhances Treg function and stability. However, it is unknown how RA receptor signaling in Tregs influences these processes in vivo. Herein, we employed mouse models in which RA signaling is silenced by the expression of the dominant negative receptor (DN) RARα in all T cells. Despite the fact that DNRARα conventional T cells are hypofunctional, Tregs had increased CD25 expression, STAT5 pathway activation, mTORC1 signaling and supersuppressor function. Furthermore, DNRARα Tregs had increased inhibitory molecule expression, amino acid transporter expression, and metabolic fitness and decreased antiapoptotic proteins. Supersuppressor function was observed when wild-type mice were treated with a pharmacologic pan-RAR antagonist. Unexpectedly, Treg-specific expression of DNRARα resulted in distinct phenotypes, such that a single allele of DNRARα in Tregs heightened their suppressive function, and biallelic expression led to loss of suppression and autoimmunity. The loss of Treg function was not cell intrinsic, as Tregs that developed in a noninflammatory milieu in chimeric mice reconstituted with DNRARα and wild-type bone marrow maintained the enhanced suppressive capacity. Fate mapping suggested that maintaining Treg stability in an inflammatory milieu requires RA signaling. Our findings indicate that RA signaling acts as a rheostat to balance Treg function in inflammatory and noninflammatory conditions in a dose-dependent manner.

Indexed as

T-Lymphocytes, RegulatoryTretinoinAnimalsAutoimmunityImmune ToleranceMiceSignal TransductionTretinoinAutoimmunityMetabolismmTORC1Retinoic acidSTAT5Tregulatory cells

Identifiers

PMID35581350
PMCPMC9243059
OpenAlexW4280535787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.